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Aims: To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in
adults with type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Using nested case-control design in electronic health record data in England, one case with first or
recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. HbA1C
variability was determined by standard deviation of ≥3 HbA1C results. Conditional logistic models were applied
to determine association of HbA1C variability with first and recurrent HH.
Results: In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI,
1.25–2.89) and 392% higher recurrent HH risk (95% CI, 1.17–20.61). In T2D, a 1.0% increase in HbA1C variability
was associated with 556% higher first HH risk (95% CI, 3.88–11.08) and 573% higher recurrent HH risk
(95% CI,1.59–28.51). In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea
users (P b 0.0001); for recurrent HH, the association was stronger in insulin users than sulfonylurea users
(P = 0.07). The HbA1C variability-HH association was stronger in more recent years in T2D (P ≤ 0.004).
Conclusions: HbA1C variability is a strong predictor for HH in T1D and T2D.1. Introduction
As a major barrier of diabetes management,1 severe hypoglycemia
affects up to 30% of people with type 1 diabetes (T1D) annually2 and
is not uncommon in individuals with long-standing type 2 diabetes
(T2D) or treated with insulin or sulfonylurea.3,4 Severe hypoglycemia
can potentially cause dire short-term consequences including comay the Sanofi Global Nutrition
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Davis).and death,5 and is also related to long-term harms including vascular
events, dementia, and mortality.6,7
HbA1C has been associated with severe hypoglycemia, although the
shape of the association remains controversial.8–12 However, data
regarding the association between HbA1C variability and severe hypo-
glycemia are limited and inconsistent. One study reported a positive
association of HbA1C variability with severe hypoglycemia13 while the
other study found a J-shaped association.14 All other studies focused
on HbA1C variability and chronic vascular complications of diabetes,15
not acute complications such as hypoglycemia. Short-term glycemic
variability (calculated fromblood glucose) is a strong predictor of hypo-
glycemia in diabetes.16 However, HbA1C variability is a different mea-
sure of glycemic control, reflecting long-term glycemic variability. In
fact, HbA1C is notmeaningfully affected by short-termglycemic variabil-
ity after accounting for mean blood glucose.17
Accordingly, the relationship between HbA1C variability and severe
hypoglycemia is unclear. Further, it is not known if differential associa-
tions exist between diabetes types or different patient characteristics. In
addition, severe hypoglycemia is recurrent and is a strong predictor of
future severe hypoglycemia.18 However, no study has compared the as-
sociation of HbA1C variability betweenfirst and recurrent hypoglycemia.
Using primary care data from the Clinical Practice Research Datalink
(CPRD) and linked secondary care data from theHospital Episode Statis-
tics (HES) in the United Kingdom (UK), the current study focused on a
most severe form of hypoglycemia which requires hospitalization. We
designed a nested case-control study to determine the association of
HbA1C variability with first and recurrent hypoglycemia hospitalization
in adults with T1D or T2D.
2. Participants and methods
2.1. Data sources
The CPRD is a primary care database that contains anonymous longi-
tudinal electronic medical records from N680 practices in the UK.19
Over 15million patient records are collected who are broadly represen-
tative of the UK population in terms of age, gender, and ethnicity.
Patient-level admitted care data are from the HES that stores every hos-
pital admission to National Health Service hospitals in England. Clinical
entries in the HES are coded using ICD-10 codes (international classifi-
cation of diseases, 10th revision) while the CPRD uses Read codes, a hi-
erarchical clinical coding system in General Practice in the UK.20 Our
study population is all patients registered with the 398 of 684 CPRD
practices that agreed to be linked to the HES between April 1,
1997 and March 31, 2014. Hypoglycemia hospitalizations were ex-
tracted from the HES and the CPRD provided all other data. The
study protocol (15_259RA) was approved by the Independent Sci-
entific Advisory Committee for Medicines and Healthcare Products
Regulatory Agency in the UK, and by the Institutional Review
Boards at the University of North Carolina at Chapel Hill in the
United States. The CPRD also had ethics approval from the National
Health Service (NHS) Research Ethics Committee for observational
studies.
2.2. Definition of incident T1D and T2D and follow-up window
We used previously published algorithm for T1D and T2D from the
CPRD.21 Among patients with at least one diabetes-related Read code,
we defined T1D as having any one of those: (i) ≥1 T1D code and insulin
use only; (ii) ≥1 T1D code and insulin use only on the diagnosis date and
non-insulin glucose-lowering drug (NIGLD), if any, was introduced
6 months later; (iii) ≥2 insulin prescriptions only. T2D was defined as
one of the following: (i) ≥2 T2D codes and 0 T1D code, regardless of
GLD use; (ii) ≥1 T2D code and 0 T1D code and NIGLD use only; (iii)
≥1 T2D code and 0 T1D code and on both NIGLD and insulinwith insulin
prescribed later; (iv) ≥2 classes of NIGLD; (v) ≥2 prescriptions of a non-
insulin non-metformin GLD. NIGLD included metformin, sulfonylurea,
glinide, thiazolidinediones, inhibitors of dipeptidyl peptidase-4 (DPP-
4), inhibitors of sodium-glucose co-transporter 2 (SGLT-2), glucagon-
like peptide-1 (GLP-1) receptor agonists, and acarbose. Patients were
excluded if they had a record of secondary diabetes, maturity onset dia-
betes of young, latent autoimmune diabetes in adults, and malnutrition
related diabetes. Also excluded were patients with unacceptable data
quality determined by the CPRD team.
The first diabetes visit date was either the earliest date of a diabe-
tes related code or a GLD prescription, whichever was earlier. Inci-
dent T1D and T2D cases were those with the first diabetes
visit N 365 days after registration.22 The follow-up started at the
maximum date of the following: April 1, 1997, first diabetes visit, pa-
tient registration, Up To Standard (UTS) date,19 or 18 years old.
Follow-up ended at the minimum date of the following: March 31,
2014, death, transfer out, last data collection for the practice, and
hospital admission for hypoglycemia.2.3. Hypoglycemia hospitalization and HbA1C variability
Hypoglycemia (E16.0, E16.1 and E16.2) as primary diagnosis for
hospitalization was identified. We recorded both the first and second
hypoglycemia hospitalization during follow-up. Individuals having ≥3
HbA1C test results prior to the first hypoglycemia hospitalization were
included. HbA1C variability was measured by standard deviation (SD)
of the available HbA1C results, accounting for the number of HbA1Cmea-
surements. HbA1C results recorded with different units were converted
to % using equations found here: http://www.ngsp.org/ifccngsp.asp.
2.4. Nested case-control design
A nested case-control design was chosen to use electronic health
data efficiently, to ensure the time comparability for computing
HbA1c variability due to its time-varying nature, and to improve statis-
tical efficiency.23,24 Diabetes duration in days was used as the time scale
for selecting 1 control for each case using incidence density sampling
method.25 Thus, controls who had not experienced hypoglycemia hos-
pitalization had the same number of days with diabetes as matched
cases. For T1D, cases and controls were additionally matched on
age± 5 years, gender, weight status (normal/underweight, overweight,
and obese), Charlson comorbidity score (≤2, 3–4, and ≥5), and having
≥3 HbA1C results. For T2D, cases and controls were also matched on
age± 5 years, gender, weight status (normal/underweight, overweight,
and obese), Charlson comorbidity score (≤3, 4–5, and ≥6), current
use (yes/no) of insulin, sulfonylurea, metformin, DPP-4 inhibitor,
thiazolidinedione, and acarbose, and having ≥3 HbA1C results. No
cases with hypoglycemia hospitalization used GLP-1 receptor agonist,
glinide or SGLT-2 inhibitor. Charlson score containing 17 comorbidities
was calculated according to Khan et al.'s approach.26 All codes are avail-
able on a web repository at www.ClinicalCodes.org.27
2.5. Statistical analysis
We studied T1D and T2D, and first and recurrent hypoglycemia hos-
pitalization, separately and respectively. The differences in demograph-
ic and clinical characteristics between cases and controls were tested
using Student's t, χ2, or Fisher's exact tests. Non-linearity of the associ-
ation between HbA1C variability and first or recurrent hypoglycemia
hospitalizationwas explored by theProcGamprocedure in SAS (version
9.4, SAS Institute Inc.) and was displayed graphically using polynomial
terms in the fully adjusted conditional logistic regression model. If the
association was linear, HbA1C SD in its continuous form was used as
the exposure. If the association was not linear, a quadratic and a cubic
term of HbA1C SD were added to capture the non-linearity. The models
were adjusted formatching variables specified above and the number of
HbA1C tests, but age, BMI, and Charlson score were added as continuous
variables to control for residual confounding, as they were matched by
broad categories. Other covariates were also adjusted for including
years of registration, current smoking, current alcohol drinking, current
prescription of antihypertensive drugs (including alpha-blockers, beta-
blockers, calcium channel blockers, angiotensin II receptor blockers,
angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics,
and nitrates), and specific diseases that may cause hypoglycemia (in-
cluding chronic pancreatitis, pancreatic adenoma, pituitary adenoma,
cystic fibrosis, hypopituitarism, and adrenal insufficiency). Finally, the
average of all available HbA1C results prior to the first hypoglycemia
hospitalization and its quadratic term were additionally included as co-
variates, since a U-shaped HbA1C–severe hypoglycemia association was
reported.10 Adjusting for the HbA1C result closest but prior to the first
hypoglycemia hospitalization only minimally affected the results.
The interaction of HbA1C variability with age, gender, BMI, Charlson
comorbidity score, current use of GLD, and calendar yearwas tested. If P
value was b0.05, stratified analyses were performed. A sensitivity anal-
ysis was conducted to evaluate whether the potential misclassification
of diabetes type may influence obtained results. Previous analyses
found that the criteria ii and iii for T1D and criterion iii for T2Dmaymis-
classify approximately 11.8% and 0.33% of T1D and T2D cases,
respectively.21 We re-analyzed the HbA1C variability-hypoglycemia as-
sociation by deleting these patients. Another sensitivity analysis was
conducted to restrict recurrent hypoglycemia hospitalization within
3 months or 1 year rather than including recurrent hypoglycemia
hospitalization at any time in T2D. The sample size in T1D did not
allow this restriction. Odds ratios (ORs) and 95% confidence intervals
(CIs) were estimated. Statistical significance was indicated by a two-
tailed P value b 0.05.
3. Results
3.1. Characteristics of cases and matched controls
In T1D adults, 193 cases of first hypoglycemia hospitalization and 41
cases of recurrent hypoglycemia hospitalization were matched
(Table 1). Cases with first hypoglycemia hospitalization had higher
HbA1C SD than controls (mean ± SD: 1.13 ± 0.72 versus 0.92 ± 0.51,
P=0.0009) and higher mean HbA1C (P=0.04). No difference between
cases and controls was found in terms of age, gender, diabetes duration,
BMI, Charlson score, years of registration, current smoking, current
drinking, antihypertensive drug use, and having diseases that may in-
duce hypoglycemia. Cases with recurrent hypoglycemia hospitalization
had higher HbA1C SD than controls (P=0.054) and higher mean HbA1C
(P=0.02) and no other differencewas seen. Themedian and interquar-
tile range of the time between the first and second hypoglycemia hospi-
talization was 0.75 ± 2.43 years.
In T2D adults, 1361 cases of first hypoglycemia hospitalization and
178 cases of recurrent hypoglycemia hospitalization were matched
(Table 2). Compared to controls, caseswith first hypoglycemia hospital-
ization had higher HbA1C SD (mean ± SD: 1.23 ± 0.61 versus 1.01 ±
0.59, P b 0.0001), higher mean HbA1C (P b 0.0001), and were less likely
to drink alcohol currently (P = 0.0006). Cases with recurrent hypogly-
cemia hospitalization had higher HbA1C SD than controls (P b 0.0001),Table 1
Characteristics of cases with hypoglycemia hospitalization and matched controls in adults with
First occurrence
Cases (N = 193) Controls (N =
HbA1C standard deviation, % 1.13 ± 0.72 0.92 ± 0.51
Number of HbA1C test 12.82 ± 9.99 12.94 ± 9.22
Mean HbA1Cb, % 8.74 ± 1.61 8.40 ± 1.62
Mean HbA1Cb, mmol/mol 72.06 ± 17.55 68.28 ± 17.75
Matching variables
Age 52.17 ± 20.84 52.06 ± 21.02
Male 56.48 56.48






Charlson score ≤ 2 51.30 51.30
Charlson score = 3 or 4 32.64 32.64
Charlson score ≥ 5 16.06 16.06
Other variables
Years of registration 31.04 ± 14.23 30.67 ± 14.83
BMI 25.30 ± 4.93 25.48 ± 4.19
Charlson comorbidity score 2.78 ± 1.93 2.65 ± 1.73
Current smoker 25.39 23.32
Current alcohol drinker 19.69 25.91
Use of antihypertensive drugsc 52.85 49.74
Diseases that may induce hypoglycemiad 5.18 3.11
Data were given as the mean ± SD or %. P value from chi-square test, Fisher's exact-test, or Stu
a The median and interquartile range of the time between the first and second hypoglycemi
b Average of all previous HbA1C results.
c Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor b
d Included chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, hypohigher mean HbA1C (P b 0.0001) and were more likely to have disease
that may induce hypoglycemia (P = 0.03). The median and interquar-
tile range of the time between the first and second hypoglycemia hospi-
talization was 0.28 ± 1.27 years.
3.2. HbA1C variability and hypoglycemia hospitalization
In T1D adults, the association between HbA1C variability and first or
recurrent hypoglycemia hospitalization was linear (Fig. 1A and B).
Every 1.0% increase in HbA1C variability was associated with 90% higher
risk of first hypoglycemia hospitalization (OR, 1.90; 95% CI, 1.25 to 2.89;
P = 0.003) and 392% higher of recurrent hypoglycemia (OR, 4.92; 95%
CI, 1.17 to 20.61; P = 0.03). Adjusting for mean HbA1C attenuated the
association for first (OR, 1.77; 95% CI, 1.15 to 2.73; P=0.01) and recur-
rent hypoglycemia hospitalization (OR, 2.75; 95% CI, 0.59 to 12.71; P=
0.20). No effect modification by age, gender, BMI, Charlson score or cal-
endar year was found.
In T2D adults, higher HbA1C variability was associated with higher
risk of first or recurrent hypoglycemia hospitalization (P b 0.0001),
but the association was not linear and the increase in the association
reached a plateau or slowed down when HbA1C variability was N1.5%
(Fig. 2A and B). A 1.0% increase in HbA1C variability was associated
with 556% higher risk of first hypoglycemia hospitalization (OR, 6.56;
95% CI, 3.88 to 11.08; P b 0.0001) and 573% higher of recurrent hypogly-
cemia (OR, 6.73; 95% CI, 1.59 to 28.51; P = 0.01). Adjusting for mean
HbA1C attenuated the association for first (OR, 4.48; 95% CI, 2.54 to
7.88; P b 0.0001) and recurrent hypoglycemia hospitalization (OR,
2.94; 95% CI, 0.60 to 14.49; P = 0.18).
In T2D adults, the association between HbA1C variability and first
hypoglycemia hospitalization was stronger in non-insulin non-
sulfonylurea users and in more recent years (P b 0.0001, Fig. 3A and
B). However, the association was similar between current insulin
users and sulfonylurea users. For recurrent hypoglycemia hospitaliza-
tion, the associationwas stronger in current insulin users than sulfonyl-
urea users (P = 0.07, Fig. 3C); the estimate for non-insulin non-
sulfonylurea users was not available due to the small sample size. Still,type 1 diabetes.
Re-occurrencea
193) P Cases (N = 41) Controls (N = 41) P
0.0009 1.23 ± 0.75 0.94 ± 0.57 0.054
0.90 14.66 ± 11.85 12.85 ± 7.24 0.41
0.04 8.87 ± 1.68 8.10 ± 1.15 0.02
0.04 73.40 ± 18.33 65.03 ± 12.52 0.02
0.96 54.61 ± 20.47 54.59 ± 20.22 0.99
1.00 53.66 53.66









0.80 30.01 ± 13.11 33.03 ± 16.72 0.37
0.70 25.21 ± 3.99 25.69 ± 3.97 0.59
0.47 3.07 ± 1.75 3.02 ± 1.78 0.90
0.64 24.39 12.2 0.15
0.15 21.95 31.71 0.32
0.54 63.41 58.54 0.65
0.31 7.32 4.88 0.64
dent's t-test, as appropriate.
a hospitalization was 0.75 ± 2.43 years.
lockers, angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics and nitrates.
pituitarism, and adrenal insufficiency.
Table 2
Characteristics of cases with hypoglycemia hospitalization and matched controls in adults with type 2 diabetes.
First occurrence Re-occurrencea
Cases (N = 1361) Control (N = 1361) P Cases (N = 178) Control (N = 178) P
HbA1C standard deviation, % 1.23 ± 0.61 1.01 ± 0.59 b0.0001 1.33 ± 0.69 1.06 ± 0.60 b0.0001
Number of HbA1C test 19.38 ± 11.68 18.65 ± 11.12 0.09 19.26 ± 11.30 19.60 ± 12.52 0.79
Mean HbA1Cb, % 8.06 ± 1.25 7.65 ± 1.23 b0.0001 8.43 ± 1.37 7.81 ± 1.26 b0.0001
Mean HbA1Cb, mmol/mol 64.57 ± 13.69 60.09 ± 13.43 b0.0001 68.66 ± 14.98 61.83 ± 13.79 b0.0001
Matching variables
Age 75.97 ± 10.60 75.64 ± 10.35 0.41 77.04 ± 10.44 76.87 ± 10.22 0.88
Male 52.31 52.31 1.00 54.49 54.49 1.00
Duration of diabetes, years 11.72 ± 6.22 11.72 ± 6.22 1.00 12.06 ± 6.18 12.06 ± 6.18 1.00
Weight status 1.00 1.00
Normal/underweight 32.84 32.84 38.20 38.20
Overweight 33.65 33.65 33.15 33.15
Obese 33.50 33.50 28.65 28.65
Comorbidities 1.00 1.00
Charlson score ≤ 3 37.91 37.91 37.08 37.08
Charlson score = 4 or 5 30.20 30.20 34.83 34.83
Charlson score ≥ 6 31.89 31.89 28.09 28.09
Current insulin use 39.60 39.60 1.00 58.43 58.43 1.00
Current sulfonylurea use 40.48 40.48 1.00 39.33 39.33 1.00
Current metformin use 41.07 41.07 1.00 34.83 34.83 1.00
Current DPP-4 inhibitor use 1.10 1.10 1.00 0.56 0.56 1.00
Current thiazolidinedione use 4.19 4.19 1.00 3.37 3.37 1.00
Current acarbose use 0.37 0.37 1.00 0.56 0.56 1.00
Other variables
Years of registration 30.87 ± 17.03 31.20 ± 16.46 0.60 32.63 ± 18.86 31.51 ± 16.50 0.55
BMI 28.51 ± 7.79 28.51 ± 6.52 0.99 27.34 ± 6.01 27.83 ± 6.25 0.45
Charlson comorbidity score 4.49 ± 2.28 4.34 ± 2.30 0.09 4.46 ± 2.26 4.31 ± 2.23 0.56
Current smoker 11.17 9.04 0.07 13.48 7.87 0.09
Current alcohol drinker 22.78 28.51 0.0006 19.66 27.53 0.08
Use of antihypertensive drugsc 89.49 87.14 0.06 89.33 84.27 0.16
Diseases that may induce hypoglycemiad 1.98 1.18 0.09 5.06 1.12 0.03
DPP-4, dipeptidyl peptidase-4. Data were given as the mean ± SD or %. P value from chi-square test, Fisher's exact test, or Student's t test, as appropriate.
a The median and interquartile range of the time between the first and second hypoglycemia hospitalization was 0.28 ± 1.27 years.
b Average of all previous HbA1C results.
c Included alpha-blockers, beta-blockers, calcium channel blockers, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates.
d Included chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, hypopituitarism, and adrenal insufficiency.stronger association between HbA1C variability and recurrent hypogly-
cemia hospitalization was seen in recent years than earlier years (P =
0.004, Fig. 3D).
3.3. Sensitivity analysis
None of our cases was identified by the criteria ii and iii for T1D and
criterion iii for T2D described above that may be most likely to misclas-
sify diabetes type from clinical perspectives. Also, restricting of recur-
rent hypoglycemia hospitalization within 3 months or 1 year for T2D
minimally affected the association (data not shown).
4. Discussion
We found that higher HbA1C variability was associated with higher
first or recurrent hypoglycemia hospitalization in both T1D and T2D.
The associationwas linear in T1D but not linear in T2D. In T1D, the asso-
ciation betweenHbA1C variability and recurrent hypoglycemia hospital-
ization was stronger than that for first hypoglycemia hospitalization. In
T2D, the association of HbA1C variability between first and recurrent hy-
poglycemia hospitalization was similar, but both stronger than in T1D.
In T2D, the association between HbA1C variability and first hypoglyce-
mia hospitalization was stronger in non-insulin non-sulfonylurea
users than insulin or sulfonylurea users, and in more recent years than
earlier years. For recurrent hypoglycemia hospitalization, the associa-
tion was stronger in insulin users than sulfonylurea users and in more
recent years than earlier years.
We are not aware of any study that has investigated the relationship
between HbA1C variability and severe hypoglycemia specifically in T1D
adults. Our analyses provided initial evidence that HbA1C variabilitywas
a strong risk factor for hypoglycemia hospitalization in T1D adults. Thestronger associationwith recurrent than first hypoglycemia hospitaliza-
tion may be related to the interplay among HbA1C variability, insulin
use, and previous hypoglycemia hospitalization. Insulin use is a major
cause of severe hypoglycemia in diabetes and severe hypoglycemia it-
self is a strong predictor for future severe hypoglycemia.3,18,28 Together
with greater variability in glycemic control, the higher risk of recurrent
hypoglycemia hospitalization is not unexpected in insulin users who
experienced hypoglycemia hospitalization before.
The strong positive association between HbA1C variability and hypo-
glycemia hospitalization in T2D adults from our data was consistent
with Williams et al.'s study conducted in diabetic hemodialysis
patients.13 Williams et al. did not directly explain the association, but
stated that the positive association between higher baseline HbA1C
and higher risk of hypoglycemia hospitalization was driven by higher
HbA1C variability rather than higher HbA1C per se. We found that
adjusting for mean HbA1C level attenuated the association between
HbA1C variability and hypoglycemia hospitalization, but HbA1C variabil-
ity was still a strong predictor of hypoglycemia hospitalization in T2D
adults. A different shape of the association between HbA1C variability
and hypoglycemia requiring medical attention was reported from a
large German T2D cohort who were newly transitioned to insulin
therapy, but HbA1C variability was calculated differently.14 Bonke
et al. defined HbA1C variability as the average difference between
successive HbA1C values per quarter year rather than HbA1C SD, be-
cause their patients were required to have an HbA1C measure every
quarter or half year. Bonke et al. found that the risk of hypoglycemia
requiring medical attention was the lowest when HbA1C change was
0.5% per quarter year. Smaller and greater change increased risk of
hypoglycemia, but the latter was more dramatic. However, when
using HbA1C SD, both Willams et al. and our study did not identify a
nadir in the association.
Fig. 1. A. HbA1C variability and first hypoglycemia hospitalization in type 1 diabetes B.
HbA1C variability and recurrent hypoglycemia hospitalization in type 1 diabetes The
association between HbA1C variability and hypoglycemia hospitalization was linear.
Model 1 included HbA1C SD, number of HbA1C measurements, age, BMI, Charlson
comorbidity score, years of registration, current smoking, current alcohol drinking,
current use of antihypertensive drug, and having diseases that may induce
hypoglycemia (chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic
fibrosis, hypopituitarism and adrenal insufficiency). Gender and duration of diabetes
were identically matched. Model 2 included mean HbA1C and its quadratic term. The
median and interquartile range of the time between the first and second hypoglycemia
hospitalization was 0.75 ± 2.43 years. The graph did not display the highest five
percentile of HbA1C SD because the results were not stable due to the big range of HbA1C
SD and small sample.
Fig. 2. A. HbA1C variability and first hypoglycemia hospitalization in type 2 diabetes B.
HbA1C variability and recurrent hypoglycemia hospitalization in type 2 diabetes The
association between HbA1C variability and hypoglycemia hospitalization was not linear.
Model 1 included HbA1C SD and its quadratic and cubic terms, number of HbA1C
measurements, age, BMI, Charlson comorbidity score, years of registration, current
smoking, current alcohol drinking, current use of antihypertensive drug, and having
diseases that may induce hypoglycemia (chronic pancreatitis, pancreatic adenoma,
pituitary adenoma, cystic fibrosis, hypopituitarism and adrenal insufficiency). Other
confounding variables were identically matched, including gender, duration of diabetes,
current use of insulin, sulfonylurea, metformin, thiazolidinedione, dipeptidyl peptidase-
4 inhibitor, and acarbose. Model 2 included mean HbA1C and its quadratic term. The
median and interquartile range of the time between the first and second hypoglycemia
hospitalization was 0.28 ± 1.27 years. The graph did not display the highest five
percentile of HbA1C SD because the results were not stable due to the big range of HbA1C
SD and small sample.Interpreting the association between HbA1C variability and hypogly-
cemia hospitalization needs to consider both the strength of the associ-
ation and the background incidence of hypoglycemia hospitalization.
Even a small increase in the association among patientswith high hypo-
glycemia risk (e.g., insulin or sulfonylurea users) would substantially
contribute to hypoglycemia burden.21 The stronger HbA1C variability-
hypoglycemia hospitalization association in T2D than T1D was largely
driven by T2D adults whowere not currently taking insulin or sulfonyl-
urea, although they were at low risk of hypoglycemia hospitalization.
The increased HbA1C variability in non-insulin non-sulfonylurea users
may indicate poor adherence to glucose-lowering therapy and/or
lifestyle management.29 Also, since they were not currently taking
insulin or sulfonylurea, two major hypoglycemia-causing drugs,3 pa-
tients may pay less attention to or had not been well educated with
preventing hypoglycemia. These may be possible reasons associated
with the stronger HbA1C variability-hypoglycemia hospitalization asso-
ciation in non-insulin non-sulfonylurea users. Similar to T1D adults, T2D
adults on insulin with previous hospitalization for hypoglycemia were
also at higher risk of developing recurrent hypoglycemia hospitalization
compared to non-insulin users. Thus, preventing first hypoglycemia
hospitalization is particularly important for reducing risk of futurehypoglycemia hospitalization in insulin users who have the highest
hypoglycemia risk.21
Using year 2008 as the cutoff was determined arbitrarily by splitting
cases with hypoglycemia hospitalization approximately into halves. In
fact, dichotomizing at an earlier or later year did not change the results
(data not shown). We do not know if this may be partly related to the
introduction of the Quality and Outcomes Framework (QOF) financial
incentive scheme in 2004 in the UK,30 because the data completeness
in the CPRD has been improved post-QOF period. Also, from 2003, prac-
tices within the CPRD began to use automated approaches to request
tests and receive results from laboratories. Laboratory data from this
time are likely to be more complete than earlier years when paper-
based systemswerewidely used. However, since the temporal variation
in the association of HbA1C variability with hypoglycemia hospitaliza-
tion was only found in T2D, not in T1D, we hypothesize that two other
reasons may be more plausible: i) Diabetes management strategies
have been recently shifted from emphasizing hyperglycemia control
to recommending individualized glycemic targets,31,32 particularly
after the three milestone cardiovascular trials in T2D33–35; ii) New
drugs have become available for treating T2D such as dipeptidyl
Fig. 3.A. HbA1C variability and first hypoglycemia hospitalization in type 2 diabetes by current use of glucose-lowering drugs B. HbA1C variability and first hypoglycemia hospitalization in
type 2 diabetes by calendar years C. HbA1C variability and recurrent hypoglycemia hospitalization in type 2 diabetes by current use of glucose-lowering drugs D. HbA1C variability and
recurrent hypoglycemia hospitalization in type 2 diabetes by calendar years The model included HbA1C SD and its quadratic and cubic terms, number of HbA1C measurements, age,
BMI, Charlson comorbidity score, years of registration, current smoking, current alcohol drinking, current use of antihypertensive drug, and having diseases that may induce
hypoglycemia (chronic pancreatitis, pancreatic adenoma, pituitary adenoma, cystic fibrosis, hypopituitarism and adrenal insufficiency). Gender and duration of diabetes were
identically matched along with current use of insulin, sulfonylurea, metformin, thiazolidinedione, dipeptidyl peptidase-4 inhibitor, and acarbose. For Fig. 3C, the association for non-
insulin and non-sulfonylurea users could not be estimated due to too few cases. The median and interquartile range of the time between the first and second hypoglycemia
hospitalization was 0.28 ± 1.27 years. The graph did not display the highest five percentile of HbA1C SD because the results were not stable due to the big range of HbA1C SD and small
sample.peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists
that are related to very low risk of hypoglycemia.36,37 Nonetheless,
how these may play a role in the association between HbA1C variability
and hypoglycemia hospitalization needs further investigation.
Factors associatedwithHbA1C variability have not beenwell studied.
More intensive glucose-lowering treatment, younger age, male gender,
lower high-density lipoprotein cholesterol, higher BMI, longer duration
of diabetes, having coronary artery disease, and multiple concurrent
medications have been associated with greater HbA1C variability.38–40
Future studies are encouraged to replicate these findings and also
propose feasible algorithms for identifying people at high risk of
greater HbA1C variability, which may be used to guide hypoglycemia
prevention.
Our study determined the association between long term glycemic
variability and risk of first and recurrent hypoglycemia hospitalization
in adults by diabetes type and identified critical interactions. Our work
contributed data to expand the current knowledge that HbA1C variabil-
ity is not only a critical variable for predicting chronic complications and
mortality as previously reported,15 but predicts hypoglycemia hospital-
ization, as a severe acute complication of diabetes. Limitations should be
noted. Firstly, although HbA1C SD is the most commonly used measure
for HbA1C variability, it has flaws, particularly, when the number of
HbA1C measurements is limited and the measurements are widely
spaced.14 However, the average number of HbA1C measurements was
fairly large in our study with about 13 and 19 measurements in T1D
and T2D adults, respectively. Secondly, 37.9% and 21.7% of cases withhypoglycemia hospitalization from T1D and T2D were excluded due to
missing data or not having three or more HbA1C results (Supplemental
Tables 1 and 2). Thus, our results may not be generalized to all patients
with diabetes in the CPRD, because the included cases differed from the
excluded cases. Thirdly, diabetes typemay have been incorrectly classi-
fied. However, none of the caseswith hypoglycemia hospitalizationwas
captured by “likely-to-misclassify” criteria according to the sensitivity
analysis. Fourthly, residual confounding is likely. For example, we
were unable to account for severe hypoglycemia without leading to
hospitalization or hypoglycemia hospitalization that occurred before
April 1, 1997 when relevant HES data were not available. Fifthly, we
only studied hypoglycemia resulting in hospitalization. Applying our
findings to other forms of hypoglycemia should be cautious. Sixthly,
we were not able to account for the potential differences that may be
created by different HbA1C determination methods. Lastly, due to the
nature of the study design, the causality of the association between
HbA1C variability and hypoglycemia hospitalization could not be
established.
In conclusion, HbA1C variability may be an important target for hy-
poglycemia prevention and management in T1D and T2D, in addition
to HbA1C. Preventing first hypoglycemia hospitalization is important
because the association between HbA1C variability and hypoglycemia
hospitalization was strengthened among those with previous hospitali-
zation for hypoglycemia, particularly in insulin users regardless of
diabetes type. Further research is needed to confirm our findings, to ex-
plainwhyHbA1C variability-hypoglycemia hospitalization association is
stronger in more recent years in T2D, and to elucidate the relevant
mechanisms linking HbA1c variability and hypoglycemia risk in
diabetes.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jdiacomp.2017.10.008.
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